Somewhat Positive Press Coverage Somewhat Unlikely to Affect Edwards Lifesciences (EW) Share Price
News stories about Edwards Lifesciences (NYSE:EW) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edwards Lifesciences earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 47.0961987469346 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Cramer’s lightning round: The analysts downgrading Edwards Lifesciences are ‘knuckleheads’ (finance.yahoo.com)
- South Texas Money Management LTD Stake in Edwards Lifesciences (EW) Has Increased by $314574; Oxford … – Hill Country Times (hillcountrytimes.com)
- Edwards Lifesciences Corp (EW) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- How Edwards Lifesciences’ Critical Care Business Is Positioned (finance.yahoo.com)
- Milestones Edwards Lifesciences Expects to Reach in 2018 (finance.yahoo.com)
A number of equities analysts have recently issued reports on the stock. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday, December 10th. BMO Capital Markets restated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Friday, December 8th. Canaccord Genuity restated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Barclays upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Finally, SunTrust Banks set a $124.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus target price of $129.57.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. During the same period in the previous year, the company posted $0.68 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. sell-side analysts predict that Edwards Lifesciences will post 3.76 EPS for the current fiscal year.
Edwards Lifesciences announced that its Board of Directors has approved a share repurchase program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $116.45, for a total transaction of $617,185.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the sale, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 210,480 shares of company stock worth $23,056,527. Insiders own 2.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Edwards Lifesciences (EW) Share Price” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-edwards-lifesciences-ew-share-price/1801895.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.